JMP maintains Human Genome at market outperform

Human Genome Sciences, Inc. was maintained by JMP Securities analyst Charles C. Duncan at a market outperform rating with a $15 price target as increased visibility at medical meetings is expected to improve the stock's performance. Shares have underperformed the sector, JMP said, mainly due to the phase 2 Lymphostat-B study in lupus not showing statistically significant improvement in symptoms. But, JMP said it believes ongoing clinical development programs in HCV, RA and oncology should enhance investor confidence and drive share price appreciation. Shares of the Rockville, Md., biopharmaceutical company were up $0.19, or 2.11%, at $9.21 on volume of 3,413,340 shares versus the three-month running average of 3,490,490 shares.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.